Table of Contents
Umbilical cord blood stem cells are potential stem cells that can convert into any type of -determined cells. Global stem cell market is dominating the healthcare industry with its reliable and cost effective method of treatment with fewer side effects. Current market for cord blood therapeutics accounts for $6.5 billion, which is expected to grow at 33.4% CAGR from 2013-2020. Other segments of this market include - Adult stem cell and embryonic stem cells. Government authorities are supporting the research and clinical trials of cord blood stem cell, which is currently increasing the interest of healthcare companies to invest in research and commercialization of cord blood stem cell therapies. Athersys, California Stem Cell Inc., and Cytori Therapeutics Inc. are engaged in the development of novel stem cell therapies from cord blood. Ethical issues regarding cord blood sample application is creating biasness among donor, which is majorly influencing the market.Competition is currently intense with companies trying to create brand awareness. This is therefore, compelling the market players to formulate market based strategies. Cord blood stem cell is the only type of stem cell that is stored in controlled condition due to its lower volume higher cell count feature. Storage service market is expected grow at 33.4% CAGR from 2013-2020.
This report provides market intelligence with respect to therapies, applications and storage services in cord blood stem cell marketDetailed analysis of top factors influencing the growth of UCB stem cell market so that companies can take developmental decisionValue chain analysis, Porter’s five forces, top investment pockets are analysed and presented in detail in the reportIntelligence of important regulatory and reimbursement issues is provided according to geographies so that companies can take strategic decisionsSWOT analysis and strategic developments included in the report for Key players: Advanced Cell Technology, Inc. (USA), Athersys, California Stem Cell Inc., Cytori Therapeutics Inc., Mesoblast, Opexa Therapeutics Geron Corporation, Neostem Inc.
KEY MARKET SEGMENTS
GLOBAL MARKET, BY STORAGEPublic cord blood banksPrivate cord blood banksPublic Vs. Private UCB banksGLOBAL MARKET, BY DISEASESCancer/ Oncology diseasesAcute LeukemiaChronic LeukemiaHigh Risk Solid TumorsMyelodysplastic SyndromeBlood diseasesAplastic AnemiaBeta ThalassemiaSickle Cell disease Immune DisordersLeukocyte Adhesion DeficiencyHystiocytic DisordersWiskott-AldrichMetabolic DisordersKrabbe DiseaseHurler SyndromeSanfilippo SyndromeOther diseasesOsteopetrosisHemophagoyticlymphohistiocytosisGLOBAL MARKET BY, TECHNOLOGYStem Cell TransplantAutologous transplantAllogenic transplantTransplant MedicineRegenerative MedicineOthersCord Blood BankingBlood TransfusionCell Based GeneticsGLOBAL MARKET,
UCB market in North AmericaUCB market in EuropeUCB market in Asia-pacificUCB market in ROW
Therapeutics service companiesPrivate and government research institutesAcademic InstitutesResearch based pharmaceutical companiesPublic and Private cord blood banks
Get Industry Insights. Simply.
Talk to Ahmad
+1 718 618 4302
Global Autologous Cell Therapy Market: Overview This report provides in-depth region wise and country wise analysis of the autologous cell therapy market. Stakeholders of this report include manufacturers ...
The global top 10 bioprocess technology market is expected to reach USD 71.03 billion by 2021 from USD 39.30 billion in 2016, at a CAGR of 12.4% from 2016 to 2021. On the basis of type, the market is segmented ...
The global stem cell therapy market is estimated to grow at a CAGR of 11.0% during 2016 to 2021 to reach USD 145.8 million by 2021. Growth in the global stem cell therapy market is driven by factors such ...